MedTrace Logo

Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

NCT07623668 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2026-08-11

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).

Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).

Conditions

Interventions

DRUG

Privosegtor

Privosegtor (OCS-05) 3 mg/kg/day IV for 5 treatment days

DRUG

Methylprednisolone

Methylprednisolone 1 g/day IV for 5 treatment days

OTHER

Placebo

0.9% sodium chloride (NaCl) solution IV for 5 treatment days

Sponsors & Collaborators

  • Oculis

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-28
Primary Completion
2027-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07623668 on ClinicalTrials.gov